APPLICATIONS



A Rapid and Robust Sample Preparation Method for Quantitation of Nicotine from Oral Fluid

Daniel Spurgin, Sean Orlowicz, and Shahana Huq Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Overview

TN-0110

- Single cartridge solid phase extraction of nicotine, anabasine, and cotinine from oral fluid
- · Resolution of nicotine and anabasine isomers
- · Linear regression values (R) of greater than 0.997

Introduction

Nicotine, its metabolite cotinine, and anabasine, a tobacco alkaloid, are often used to detect tobacco exposure. For tests like this, oral fluid collection has emerged as an alternative to other biological matrices. The reason for its popularity is due to its low chance of adulteration. In addition, oral fluid collection is easy and non-invasive. As a test matrix, oral fluid shows great promise for detection of recent drug use, its disposition, and detection times.¹ However, it is not free of challenges. The additives and preservative buffer (critical for preservation of the chemical integrity of the oral fluid sample) present in the collection devices, must be removed for the proper upkeep of the mass spec detector.

In this technical note, we present a solid phase extraction (SPE) method for simultaneous detection and quantitation of nicotine, cotinine, and anabasine from oral fluid. We employ Intercept i2[®], a commercially available oral fluid collection device for sample collection and transport. A polymeric, strong cation-exchange sorbent, Strata[®]-X-C was utilized for solid phase extraction (SPE). pH stable Kinetex[®] 2.6 µm EVO C18 column was used for the analysis purposes to obtain the best selectivity between the two isomeric compounds nicotine and anabasine under an ESI mode in LC-MS/MS analysis.

Materials and Methods

Analytical reference standards were purchased from Cerilliant[®] Corporation (Round Rock, TX). Negative calibrator oral fluid and Intercept i2 collection device were obtained from OraSure Technologies (Bethlehem, PA). All other chemicals, were obtained from the Sigma-Aldrich Company (St. Louis, MO). Ultrapure DI water was obtained from Sartorius[®] arium[®] comfort II, courtesy of Sartorius Corporation (Bohemia, NY)

Experimental Conditions

Calibrators for the 7-point linearity curve were prepared by serial dilution of the negative oral fluid control. The curve spans a total of seven concentration levels, covering a wide range. The QC samples for extraction were prepared at three concentration (low, medium and high) levels.

Sample Collection and Pretreatment

Oral fluid specimens, calibrators, and QC samples were collected on the cellulose pad (on a plastic stick from Intercept i2 devices) until the indicator window turns blue. The saturated pad on the stick was then placed into the transport tube containing the buffer solution and left overnight to represent transit time. The plastic nipple from the transport tube was removed and cellulose tab was placed in a centrifuge tube, which was centrifuged at 600 g for 15 mins. The supernatant was collected for sample preparation.

SPE Method

Step	Basic analyte extraction
96-Well Plate:	Strata-X-C, 30 mg
Part No.:	8E-S029-TGB
Condition:	1 mL Methanol
Equilibrate:	1 mL DI Water
Load:	Combine 0.5 mL of pretreated sample with 1 mL 1% Formic acid, add 40 µL working internal standard solution (0.5 µg/mL). Mix/vortex 5-10 sec and load on Strata-X-C.
Weak Wash:	1 mL DI Water
Strong Wash:	1 mL Acetone/Water (50:50)
Dry:	3-4 minutes at maximum vacuum (15" Hg or higher)
Elute:	2 x 500 μL Ethyl acetate / Isopropanol / Ammonium hydroxide (7:2:1)
Dry down:	Evaporate to dryness under gentle stream $\rm N_2$ at 45-50 $^{\circ}\rm C$
Reconstitute:	With 200 µL initial mobile phase

Revision:

PHEN-RUO-00116



APPLICATIONS







Figure 2.

Representative chromatogram of cotinine, anabasine, and nicotine from oral fluid extracted samples.



Figure 5.

Linearity curve for anabasine (1 to 500 ng/mL) from oral fluid extracted samples. R=0.9983.



Table 1.

Precision and accuracy data for 3 different levels of QC.

a) Nicotine					
Conc. (ng/mL)	Sample Name	Replicate	% CV	Accuracy	
4	QC-Low	4	8.4	97.6	_
40	QC-Med	4	3.9	92.9	
150	QC-High	4	5.1	94.0	
b) Cotinine					
Conc. (ng/mL)	Sample Name	Replicate	% CV	Accuracy	
4	QC-Low	4	10.8	84.1	_
40	QC-Med	4	4.1	97.7	
150	QC-High	4	4.6	95.2	
c) Anabasine					
Conc. (ng/mL)	Sample Name	Replicate	% CV	Accuracy	
4	QC-Low	4	3.2	95.3	
40	QC-Med	4	3.7	94.1	
150	QC-High	4	2.3	98.0	

LICATIONS

Results and Discussion

Kinetex[®] EVO C18 column was chosen because it is robust and provided the best selectivity. The isomeric species nicotine and anabasine were well resolved, as shown in **Figure 2**.

For SPE, a strong cation-exchanger sorbent, Strata[®]-X-C, was used to allow the use a 50% acetone wash. This strong organic wash effectively removed the excipients from the sample and transport buffer.² An elution solvent composing of ethyl acetate, isopropanol, and ammonium hydroxide eluted the analytes selectively, leaving any residual impurities behind.

Calibration curves were constructed from spiked saliva samples ranging from 1 to 500 ng/mL, using seven points for all three analytes. The linearity curves with a quadratic fit and 1/x weighting factor showed the correlation coefficient value (R) for all analytes more than 0.997 (**Figures 3-5**) over a wide dynamic range.

Three levels of QC samples (low, medium and high) obtained a precision and accuracy ranging from 2-10% and 84-98% respectively, for 4 replicate extraction at each concentration level (**Table 1**).

Conclusion

In this technical note we demonstrated an effective sample preparation technique for quantitation of nicotine, cotinine, and anabasine from oral fluid. This is a reliable and reproducible assay with good separation of isomeric analytes and demonstrates linear regression values (R) more than 0.997 for all analytes that reflects the robustness of the assay over a wide dynamic range.

References

- N. Robson, A. J. Bond and K. Wolff; "Salivary nicotine and cotinine concentrations in unstimulated and stimulated saliva"; African Journal of Pharmacy and Pharmacology, Vol. 4(2), 061-065, 2010.
- S. Sadjadi, S. Huq, L. Snow; "An Investigation into Removing the Excipients from Selected Oral Fluids Collection Devices by SPE and LC/MS Detection"; Mass Spec Application for Clinical Laboratory Conference, 2016.

Kinetex® EVO C18 Ordering Information

5 µm Minibore Colu	mns (mm)			SecurityGuard™ ULTRA Cartridges [‡]
30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
00A-4633-AN	00B-4633-AN	00D-4633-AN	00F-4633-AN	<u>AJ0-9298</u>
				for 2.1 mm ID
			SecurityGuard	
5 µm MidBore [™] Coli	umns (mm)	150 - 2 0	ULIKA Cartridges	
50 X 3.0	100 X 3.0	150 X 3.0	3/ pK	
<u>00B-4633-10</u>	<u>00D-4633-10</u>	<u>00F-4633-10</u>	AJU-9297	
			for 3.0 mm ID	
5 µm Analytical Colı	umns (mm)			SecurityGuard ULTRA Cartridges [‡]
50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	3/pk
00B-4633-E0	00D-4633-E0	00F-4633-E0	00G-4633-E0	<u>AJ0-9296</u>
				for 4.6 mm ID
2.6 µm Minibore Col	lumns (mm)			SecurityGuard™ ULTRA Cartridges [‡]
30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
00A-4725-AN	00B-4725-AN	00D-4725-AN	00F-4725-AN	<u>AJ0-9298</u>
				for 2.1 mm ID
2.6 um MidPoro™ Co	lumno (mm)		SecurityGuard	
2.0 µm MidBore CC	100 x 3 0	150 v 3 0	3/nk	
00B-4725-V0	00D-4725-V0	00E-4725-V0	Δ 10-9297	
000 4723 10	000 4723 10	001 4720 10	for 3.0 mm ID	
			SecurityGuard	
2.6 µm Analytical Co	olumns (mm)		ULTRA Cartridges [‡]	
50 x 4.6	100 x 4.6	150 x 4.6	3/pk	
00B-4725-E0	00D-4725-E0	00F-4725-E0	<u>AJ0-9296</u>	
			for 4.6 mm ID	
1 7 um Minihore Col	lumne (mm)		SecurityGuard	
50 x 2.1	100 x 2.1	150 x 2.1	3/nk	
00B-4726-AN	00D-4726-AN	00E-4726-AN	A 10-0208	

for 2.1 mm ID

* SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000





PI ICATIONS

The Netherlands t: +31 (0)30-2418700 nlinfo@phenomenex.com

New Zealand

Norway t: +47 810 02 005

Poland t: +48 (12) 881 0121

Portugal t: +351 221 450 488

Singapore

Spain t: +34 91-413-8613

Sweden t: +46 (0)8 611 6950

Taiwan

USA

t: +65 800-852-3944 sginfo@phenomenex.com

Switzerland t: +41 (0)61 692 20 20

United Kingdom

t: +44 (0)1625-501367

t: +1 (310) 212-0555

t: +1 (310) 212-0555

t: +64 (0)9-4780951

nzinfo@phenomenex.com

nordicinfo@phenomenex.com

pl-info@phenomenex.com

ptinfo@phenomenex.com

espinfo@phenomenex.com

nordicinfo@phenomenex.com

swissinfo@phenomenex.com

t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

ukinfo@phenomenex.com

info@phenomenex.com

info@phenomenex.com

All other countries/regions Corporate Office USA

Strata [®] -X-C Ordering Information						
Format	Sorbent Mass	Part Number	Unit			
Tube						
100 B	30 mg	8B-S029-TAK**	1 mL (100/box)			
	30 mg	8B-S029-TBJ	3 mL (50/box)			
	60 mg	8B-S029-UBJ**	3 mL (50/box)			
	100 mg	8B-S029-EBJ	3 mL (50/box)			
	100 mg	8B-S029-ECH	6 mL (30/box)			
	200 mg	8B-S029-FBJ	3 mL (50/box)			
	200 mg	8B-S029-FCH	6 mL (30/box)			
	500 mg	8B-S029-HBJ	3 mL (50/box)			
	500 mg	8B-S029-HCH	6 mL (30/box)			
Giga [™] Tube						
- WANTER -	500 mg	8B-S029-HDG	12 mL (20/box)			
Pression	1 g	8B-S029-JDG	12 mL (20/box)			
	1 g	8B-S029-JEG	20 mL (20/box)			
	2 g	8B-S029-KEG	20 mL (20/box)			
	5 g	8B-S029-LFF	60 mL (16/box)			
96-Well Plate						
	10 mg	8E-S029-AGB	2 Plates/Box			
Carde 1	30 mg	8E-S029-TGB	2 Plates/Box			
12.50	60 mg	8E-S029-UGB	2 Plates/Box			
96-Well Microelution Plate						
	2 mg	8M-S029-4GA	ea			

** Tab-less tubes available. Contact Phenomenex for details.

1005



45 days to try our products. If you are not happy, we'll make it right. www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at http://www.phenomenex.com/TermsAndConditions.

Trademarks

Kinetex and Strata are registered trademarks and MidBore, BE-HAPPY, SecurityGuard and Giga are trademarks of Phenomenex. Intercept i2 is a registered trademark of OraSure Technologies, Inc. Sartorius and arium are registered trademarks of Sartorius AG. Cerilliant is a registered trademark of Cerilliant Corporation. SCIEX is a registered trademark and Triple Quad is a trademark of AB SCIEX Pte. Ltd. AB SCIEX™ is being used under license

Kinetex EVO is patented by Phenomenex. U.S. Patent Nos. 7,563,367 and 8,658,038 and foreign counterparts

Strata-X is patented by Phenomenex, U.S. Patent No. 7,119,145 FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2020 Phenomenex, Inc. All rights reserved.

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belgium t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

Denmark t: +45 4824 8048 nordicinfo@phenomenex.com

Finland t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

India t: +91 (0)40-3012 2400 indiainfo@phenomenex.com

Ireland t: +353 (0)1 247 5405 eireinfo@phenomenex.com

Italy t: +39 051 6327511 italiainfo@phenomenex.com

Luxembourg t: +31 (0)30-2418700 nlinfo@phenomenex.com

Mexico t: 01-800-844-5226 tecnicomx@phenomenex.com

www.phenomenex.com

Page 4 of 4

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com